EGFR and non-small cell lung carcinoma: Gain-of-function EGFR mutations are the most frequent alterations observed in NSCLC, occurring in approximately 27% of NSCLC cases [139], and while targeted therapies are available for these tumor types, most patients who initially benefit from EGFR-TKIs eventually develop resistance to these agents, likely as a result of secondary genetic alterations [140].